NIH-funded research R01 grant

How a liver protein (PPARγ) may drive fatty liver disease

Official title: PPARgamma-regulated mechanisms in hepatocytes that promote NAFLD

Funded at University of Illinois at Chicago · NIH-11290380 · Data updated 2026-11-12

This project looks at whether a liver protein called PPARγ causes or worsens fatty liver disease in adults with type 2 diabetes to find better treatment targets.

More NAFLD research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Illinois at Chicago
NIH-funded
Lab location1 site (Chicago, UNITED STATES)
Project startFebruary 1, 2022
Project endJanuary 31, 2027
Funding year2026
Award (this year)$411,157
NIH project number5R01DK131038-05
Project IDNIH-11290380 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are adults with type 2 diabetes who have non-alcoholic fatty liver disease or are at high risk for NASH.

Less likely to help

People without NAFLD/NASH, or those whose liver disease is caused mainly by alcohol or other non-metabolic causes, are unlikely to benefit from these findings.

What this research studies

If I have fatty liver linked to type 2 diabetes, this project focuses on a liver protein called PPARγ that may drive the disease. Researchers will use lab models, including genetically modified mice and viral gene tools, to change PPARγ activity specifically in liver cells and measure effects on methionine metabolism and genes like PEMT and BHMT. They will also test how these liver changes affect the response to diabetes drugs called thiazolidinediones (TZDs). The goal is to find liver-specific molecular targets that could lead to safer or more effective treatments for NAFLD/NASH.

Why it matters

Potential benefit: If successful, this work could reveal liver-specific targets or strategies that prevent or treat NAFLD/NASH and improve how diabetes drugs are used for people with fatty liver.

How similar studies have gone: Previous research shows TZD drugs can help insulin resistance but their liver effects are mixed, so this builds on known findings while exploring a novel liver-specific mechanism.

Where this research is happening

  • University of Illinois at Chicago
    Chicago, United States
    Active

Researchers

  • Principal investigator: Cordoba-Chacon, Jose — University of Illinois at Chicago
  • Study coordinator: Cordoba-Chacon, Jose

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.